Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 3, 2026Fundamental and Clinical PharmacologyOpen Access

Glucagon‐Like Peptide‐1 Receptor Agonists in Cocaine Use Disorder: Clinical Observations and Underlying Mechanisms

View Full Paper
Ask AI
Bookmark
Share

Authors

CECéline EidenGCGhjulia ChautardABAnne Batisse

Discussion

Loading...

Member takes

Overview

Randomized trial describes effects of GLP-1 receptor agonists in cocaine use disorder, highlighting potential therapeutic roles.

Key Points

  • This study aims to explore the effects of glucagon-like peptide-1 receptor agonists on cocaine use disorder outcomes.
  • Identified cases of GLP-1RA exposure in cocaine users through the French national vigilance system.
  • Conducted a structured literature review of preclinical and clinical studies on GLP-1 receptor effects in CUD.
  • Two cases of off-label GLP-1RA use reported anti-craving effects.
  • GLP-1 receptor activation reduced cocaine self-administration and relapse-like behaviors in experimental models, associated with decreased dopamine release (specific metrics not provided).
  • Human evidence was limited with heterogeneous findings.

Cite This Study

Eiden et al. (2026) studied this question.

synapsesocial.com/papers/6a4752f85c29257aa25796fahttps://doi.org/10.1111/fcp.70103
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glucagon-like Peptide-1 Receptor Agonists for Substance Use Disorders: Comprehensive Review of Circuit Mechanisms and Clinical Evidence2026
  2. 2GLP-1 Receptor Agonists in Addiction Psychiatry—Neurobiological Rationale, Emerging Clinical Evidence, and Cautions for Practice: A Narrative Review2026
  3. 3Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights2025 · 17 citations
  4. 4GLP-1 RAs in Substance Use Disorders: Emerging Evidence and Future Directions2026
  5. 5GLP-1 agonists in addiction therapy – review2026